Loading
Exai Bio's study of a blood test that looks for small RNA molecules made by tumours.
Exai oncRNA prospective study by cancer size and stage (NCT05833360) is an observational study sponsored by Exai Bio Inc. It develops and evaluates the Exai oncRNA blood test for cancer detection, stratified by tumour size and stage.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 2,400 participants, a start on 14 July 2023 and primary completion expected on 14 July 2030.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/